pancreatic volume
Recently Published Documents


TOTAL DOCUMENTS

82
(FIVE YEARS 6)

H-INDEX

16
(FIVE YEARS 0)

Medicine ◽  
2021 ◽  
Vol 100 (34) ◽  
pp. e27096
Author(s):  
Lu Li ◽  
Shuang Wang ◽  
Fei Wang ◽  
Guo-ning Huang ◽  
Dong Zhang ◽  
...  






Author(s):  
Lalchhandami Colney ◽  
Nikhil Tandon ◽  
Pramod Kumar Garg ◽  
Nandita Gupta ◽  
Sushma Sagar ◽  
...  


2021 ◽  
pp. 000313482198904
Author(s):  
Tatsuya Yamazaki ◽  
Takeshi Aoki ◽  
Yoshihiko Tashiro ◽  
Tomotake Koizumi ◽  
Tomokazu Kusano ◽  
...  

Background Decreased pancreatic volume (PV) is a predictive factor for diabetes mellitus (DM) after surgery. There are few reports on PV and endocrine function pre- and post-surgery. We investigated the correlation between PV and insulin secretion. Methods Seventeen patients underwent pancreaticoduodenectomy (PD) Pre- and post-surgery PV and C-peptide index (CPI) measurements were performed. Additionally, the correlation between PV and CPI was analyzed. Results The mean preoperative PV (PPV) was 55.1 ± 31.6 mL, postoperative remnant PV (RPV) was 25.3±17.3 mL, and PV reduction was 53%. The mean preoperative C-peptide immunoreactivity (CPR) was 1.39 ± .51 and postoperative CPR was .85±.51. The mean preoperative CPI was 1.29±.72 and postoperative CPI was .73 ± .48. Significant correlations were observed between RPV and post CPR (ρ = .507, P = .03) and post CPI (ρ = .619, P = .008). Discussion There was a significant correlation between RPV and CPI after PD. A smaller RPV resulted in lower insulin secretion ability, increasing the potential risk of new-onset DM after PD.



Pancreatology ◽  
2020 ◽  
Vol 20 (8) ◽  
pp. 1732-1738
Author(s):  
Sung Woo Ko ◽  
Dong-Wan Seo ◽  
Hoonsub So ◽  
Jun Seong Hwang ◽  
Hyun Don Joo ◽  
...  


Pancreatology ◽  
2020 ◽  
Author(s):  
Takeshi Tanaka ◽  
Atsuhiro Masuda ◽  
Keitaro Sofue ◽  
Hirochika Toyama ◽  
Hideyuki Shiomi ◽  
...  


2020 ◽  
Vol 26 (4) ◽  
pp. 321-327
Author(s):  
Jihyun Yoon ◽  
Kwang Gi Kim ◽  
Young Jae Kim ◽  
Sangheon Lim ◽  
Yeon-Ho Park ◽  
...  


2020 ◽  
Vol 08 (11) ◽  
pp. E1603-E1610
Author(s):  
Tsuyoshi Takeda ◽  
Takashi Sasaki ◽  
Takafumi Mie ◽  
Takaaki Furukawa ◽  
Ryo Kanata ◽  
...  

Abstract Background and study aims Self-expandable metallic stents (SEMS) are now widely used even for patients with borderline resectable (BR) pancreatic cancer (PC), as neoadjuvant therapy has become common. Therefore, we conducted this study to evaluate safety of SEMS placement in the population including BR PC and to explore risk factors for recurrent biliary obstruction (RBO), pancreatitis, and cholecystitis. Patients and methods We retrospectively investigated consecutive patients with PC who received initial SEMS between January 2015 and March 2019. We compared time to RBO (TRBO), causes of RBO, and stent-related adverse events (AEs) according to resectability status. Univariate and multivariate analyses were performed to explore risk factors for TRBO, pancreatitis, and cholecystitis. Results A total of 135 patients were included (BR 31 and unresectable [UR] 104). Stent-related AEs occurred in 39 patients: pancreatitis 14 (mild/moderate/severe 1/6/7), cholecystitis 12, and non-occluding cholangitis 13. TRBO, causes of RBO, and stent-related AEs were not significantly different according to resectability status. Overall rate of RBO was higher in UR PC due to the longer follow-up period. Sharp common bile duct (CBD) angulation was an independent risk factor for short duration of TRBO. High pancreatic volume index and SEMS of high axial force were independent risk factors for pancreatitis, whereas tumor involvement to orifice of cystic duct was the only risk factor for cholecystitis. Conclusions We demonstrated that SEMS can be safely deployed even in patients with BR PC. Sharp CBD angulation and high pancreatic volume index were identified as novel risk factors for RBO and pancreatitis, respectively, after SEMS placement.



Sign in / Sign up

Export Citation Format

Share Document